Range
66.69 - 70.8
Vol / Avg.
369.5K/630.8K
Div / Yield
-
52 Wk
32.64 - 85.4
Mkt Cap
5.2B
Payout Ratio
-
Open
69.43
P/E
136.68
EPS
18.42
Shares
77M
Outstanding
77M
Total Float
-
Benzinga - Aug 31, 2021, 6:03AM
load more
Sector: Health Care.Industry: Biotechnology
I-MAB Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.

Earnings

see more
H1 2021Est.ActualSurprise
EPS-1.540
REV2.753M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
IMABI-MAB-3.27%5.2B

I-MAB Questions & Anwsers

Q

How do I buy I-MAB (IMAB) stock?

A

You can purchase shares of I-MAB (NASDAQ: IMAB) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for I-MAB (IMAB) stock?

A

The latest price target for I-MAB (NASDAQ: IMAB) was reported by HC Wainwright & Co. on September 1, 2021. The analyst firm set a price target for 95.00 expecting IMAB to rise to within 12 months (a possible 39.71% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for I-MAB (IMAB)?

A

The stock price for I-MAB (NASDAQ: IMAB) is $68 last updated Fri Sep 24 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does I-MAB (IMAB) pay a dividend?

A

There are no upcoming dividends for I-MAB.

Q

When is I-MAB (NASDAQ:IMAB) reporting earnings?

A
I-MAB’s H1 earnings are confirmed for after-market on August 31, 2021.
Q

Is I-MAB (IMAB) going to split?

A

There is no upcoming split for I-MAB.

Q

What sector and industry does I-MAB (IMAB) operate in?

A

I-MAB is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.